Pipeline Overview

Armata’s therapeutic phage candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed in partnership with Merck. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing.

divider
Pathogen / Indication Discovery Preclinical IND-Enabling CMC Phase 1b/2
Pseudomonas aeruginosa
CF Lung Infections
AP-PA02
Pneumonia
Staphylococcus aureus
Bacteremia
AP-SA02
 US DoD*
Other Indication
Phage Candidate Pathogen &
Indication		 Phase Partner
AP-PA02 P. aeruginosa
CF Lung Infection		 Phase 1b/2 (2020)
AP-SA02 S. aureus
Bacteremia		 Phase 1b/2 (2021) US DoD*
*Department of Defense (Naval Medical Research Center, US Army Medical Research Acquisition Activity, Defense Health Agency)
Discovery-Stage
Engineered Phage
undisclosed target/indication		Merck
Escherichia coli
Klebsiella pneumoniae
Discovery-Stage
Engineered Phage
undisclosed		Merck
Escherichia coli
Klebsiella pneumoniae